Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
The effect of 300 mg Fenofibrate daily on serum lipoprotein concentrations was studied for 6 month in 32 subjects with primary familial hyperlipoproteinemias. In summary Fenofibrate lowered already after one month of therapy the mean cholesterol serum concentrations by 20-25% and serum triglyceride concentrations by 40-45%, when compared with placebo therapy. The greatest effectiveness in the lowering of atherogenic lipoproteins was recorded in type IIa and type III, while good effectiveness was experienced in type IV, though with a limitation of an increase of LDL2 at the upper limit of the normal range. In the case of type II b the effectiveness was limited only to VLDL. Moreover Fenofibrate treatment leads to normalization of lipid composition of the lipoproteins. The HDL showed besides an increase of HDL-phospholipids in type II a no further significant changes. That leads to a more favourable antiatherogenic index, i.e. the relation of HDL-chol. : (LDL-chol. + VLDL-chol.), in all types. The results of this study confirmed that Fenofibrate is a well tolerated drug, which efficiently lowers elevated lipoprotein concentrations.